3 Reasons GlaxoSmithKline's Stock Could Fall

Shares of U.K. pharma giant GlaxoSmithKline have sputtered this year. Here are three reasons why they could fall even further.

Sep 4, 2014 at 8:20AM

Big pharmas have been a mixed bag this year in terms of the performance of their stock prices. Some companies like Merck & Co. (NYSE:MRK) have seen their stock prices soar as their reorganization and clinical efforts have helped to turn the tide against the so-called patent cliff. 

British pharma giant GlaxoSmithKline (NYSE:GSK), by contrast, has struggled mightily this year in the face of falling revenues, clinical setbacks, and widespread allegations of bribery in far flung countries like Syria and China. As a result of these problems, Glaxo's shares have drastically underperformed the broader market over the past year, as shown by the chart below.

GSK Chart

GSK data by YCharts

While there are no guarantees that a certain stock will either rise or fall over any particular time period, it's always a good idea to consider the risks associated with any investment. With that in mind, here are three reasons why Glaxo's stock could continue to underwhelm moving forward.

Reason No. 1
Glaxo's best-selling respiratory drug, Advair, is losing the pricing and market share battle against AstraZeneca's (NYSE:AZN) Symbicort and Merck's Dulera. In the second-quarter, Advair sales dropped a whopping 19% compared to a year ago and experienced a 7% negative price impact because of competing drugs.

What should most concern investors is that this erosion of market share and profit margin for Advair is expected to continue for the foreseeable future and could even accelerate as newer drugs become commercially available. 

Compounding Glaxo's problems within the respiratory space, Breo doesn't look like it will be able to stem the tide anytime soon. Because Breo was recently excluded from Express Script's list of medicines eligible for reimbursement, Glaxo's strategy to transition away from Advair to Breo, and other newer respiratory drugs, has run into a significant roadblock, to put it mildly.    

Reason No. 2
The ongoing bribery investigations across six different countries have caught the eye of government officials in the U.K. and U.S. and this could translate into a massive fine. Remember, it was only about two years ago that Glaxo was hit with a record $3 billion fine from the Department of Justice for marketing some of its best-selling drugs for unapproved uses. 

Given that most of the current allegations center around bribing local doctors to increase sales, this latest incident might provoke even harsher penalties if a "pattern of corruption" is discovered. Put simply, Glaxo could be facing a big hit to its bottom line with yet another large fine. 

Reason No. 3
Unlike many other big pharmas that have increased share buybacks to help buoy their stock prices during their transition periods, Glaxo stated in its second-quarter earnings that the strength of the sterling on free cash flow means that share repurchases will be immaterial for the remainder of the year. In light of the fact that Glaxo's stock has dropped by double digits in the past six months and the company looks undervalued from a fundamental perspective, it's telling that management isn't willing to reward weary shareholders by buying back shares at this time. In short, the potential gains from buying at theoretically depressed levels should easily outweigh the negative impacts of the sterling to U.S. dollar exchange rate.

Foolish wrap-up
Glaxo presents a challenging bull vs. bear argument. On one hand, it's easy to view Glaxo as a classic value stock. After all, the stock's price-to-earnings ratio is significantly lower than the sector average, it offers an attractive dividend yield at current levels, and experts are projecting decent top-line growth next year.

On the other hand, however, Glaxo could be viewed as a value trap. Despite what look like improving fundamentals on paper, the market dynamics of the U.S. respiratory medicine market are going to prove difficult to overcome for the company's new cadre of drugs. Moreover, the possibility that Glaxo will come through unscathed from this bribery scandal is looking bleaker by the day. All told, sitting on the fence may be the best approach to this stock for the time being.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers